Evidence map›Paper›PMID 42015709›Full record

ReviewZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026

[Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia].

Yu-Qi Li, Ya-Jie Wang, Zeng-Zheng Li, Jun-Xue Ni

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu-Qi LiDepartment of Pediatrics, The First People's Hospital of Yunnan Province, Kunming 650100, China.
Ya-Jie Wang
Zeng-Zheng Li
Jun-Xue Ni

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematologic malignancy in children. High-risk B-ALL, due to factors such as poor early treatment response and adverse genetic features, is prone to drug resistance and relapse, resulting in an unfavorable prognosis and posing a major clinical challenge. In recent years, risk stratification based on molecular subtyping has driven optimization of therapeutic strategies, and precision, individualized treatment has become the focus of clinical research and practice. This review summarizes the research progress in individualized therapy for pediatric high-risk B-ALL, with the aim of providing a theoretical basis for clinical diagnosis and treatment.

Indexed as

Precision MedicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomaChildHumansB-cell acute lymphoblastic leukemiaChildHigh-riskIndividualized treatment

Identifiers

PMID42015709
PMCPMC13108925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.